Kite, a
Through this collaboration, HiFiBiO will use its proprietary technology platforms to identify novel AML targets and anti-AML specific antibodies for Kite's use in cell therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200903005169/en/
'Kite is committed to pursuing novel cell therapies for people living with AML,' said
'We look forward to working with Kite to identify disease-relevant targets directly from AML patient samples,' said
Under the terms of the agreement, HiFiBiO will receive an upfront payment and will be eligible for additional payments based on the achievement of certain research milestones. Kite will have an exclusive option to opt in on any targets discovered through the collaboration, for which HiFiBiO will receive an additional payment and will be eligible for additional development, regulatory and commercial milestone payments, as well as royalty payments.
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is transforming the field of immunotherapy by combining proprietary single-cell profiling technologies with advanced data intelligence and deep knowledge of immune system biology. This approach enables the development of novel antibody therapies that are paired with biomarkers to predict patient response. HiFiBiO Therapeutics is working actively to address unmet medical needs around the world through its own innovative pipeline programs and open-innovation partnerships with world-renowned industry and academic researchers. The company's strong global footprint features cutting-edge laboratories on three continents, in
About Kite
Kite, a
About
Gilead and Kite Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that Gilead and Kite may not realize the potential benefits of this research collaboration with HiFiBiO or other investments in cell therapy. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended
Contact:
Tel: (650) 522-2739
(C) 2020 Electronic News Publishing, source